Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02109562 · ClinicalTrials.gov registry record · Phase 3
Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients
A Phase 3 study, sponsored by Indivior.
- Completed
- Registry status
- Phase 3
- Development phase
- 354
- Enrollment target
NCT02109562 is a Phase 3 study that has completed, run by Indivior. The registered enrollment target is 354 participants.
The verdict
NCT02109562, a Phase 3 study, has completed, sponsored by Indivior.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 354 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of RBP-7000 compared with placebo in the treatment of patients with schizophrenia. This will be a double-blind, placebo-controlled, Phase III study with 90 mg and 120 mg doses of RBP-7000 compared with placebo over an 8-week treatment period.
Interventions
- DRUG Placebo
- DRUG Risperidone
- DRUG RBP-7000
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 354 participants |
| Start Date | 2014-04 |
| Est. Completion | 2014-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02109562
The ClinicalTrials.gov registry entry for NCT02109562 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 354 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indivior, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02109562 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02109562 about?
NCT02109562 is a clinical study titled "Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients". The purpose of this study is to evaluate the efficacy and safety of RBP-7000 compared with placebo in the treatment of patients with schizophrenia. This will be a double-blind, placebo-controlled, Phase III study with 90 mg and 120 mg doses of RBP-7000 compared with placebo over an 8-week treatment...
What is the current status of trial NCT02109562?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 354 participants. The study started on 2014-04. Estimated completion is 2014-11.
What interventions are being tested in trial NCT02109562?
The interventions under investigation include: Placebo (DRUG), Risperidone (DRUG), RBP-7000 (DRUG).
Who is sponsoring clinical trial NCT02109562?
This trial is sponsored by Indivior, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.